Genmab: EC Approves Expanded Darzalex Use in Multiple Myeloma

Date : 11/19/2019 @ 4:55PM
Source : Dow Jones News
Stock : Genmab AS (GMAB)
Quote : 22.17  -0.04 (-0.18%) @ 12:59AM
After Hours
Last Trade
Last $ 22.17 ◊ 0.00 (0.00%)

Genmab: EC Approves Expanded Darzalex Use in Multiple Myeloma

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

1 Month : From Nov 2019 to Dec 2019

Click Here for more Johnson and Johnson Charts.

By Colin Kellaher


Genmab A/S (GMAB.KO, GMAB) on Tuesday said the European Commission approved the expanded use of Darzalex in a form of the blood cancer multiple myeloma.

The Copenhagen biotechnology company said the EC granted marketing authorization for Darzalex in combination with lenalidomide and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplant.

Johnson & Johnson's (JNJ) Janssen Biotech Inc. unit has an exclusive license to develop, manufacture and commercialize Darzalex under an August 2012 agreement with Genmab.

The European Medicines Agency's Committee for Medicinal Products for Human Use last month recommended approval of the additional indication.


Write to Colin Kellaher at


(END) Dow Jones Newswires

November 19, 2019 11:40 ET (16:40 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest GMAB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.